Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L18a (RPL18A)
- Target
- RPL18A
- Molecular classification
- Ribosomal protein, Structural protein of the large ribosomal subunit (L18AE family), Other (not a receptor, enzyme, ion channel, transporter, transcription factor, or histone modification)
01
Overview
60S ribosomal protein L18a is a structural protein component of the large (60S) subunit of eukaryotic ribosomes[1][2][3][5]. It is encoded by the RPL18A gene and is essential for the assembly and function of the ribosome, which catalyzes protein synthesis within the cell. It belongs to the L18AE family and is specific to cytoplasmic ribosomes. RPL18A may bind RNA during ribosome assembly and has been noted to interact with hepatitis C virus RNA, with potential involvement in viral replication[3]. There are multiple pseudogenes of RPL18A dispersed throughout the genome, and its gene is co-transcribed with U68 snoRNA[1][3]. As with other ribosomal proteins, regulatory mutations or differential expression can be detected in certain pathological states, but it is not typically considered a drug target or clinical biomarker.
- Other names
- Ribosomal protein L18aLarge ribosomal subunit protein eL20eL2060S ribosomal protein L18aRPL18AL18ARibosomal protein L18a-like protein
02
Mechanism of action
Not applicable, as there are no approved drugs targeting RPL18A specifically
03
Biological functions
Structural constituent of ribosomeEssential for protein synthesisRNA bindingMay play a role in viral replication (specifically interacts with the hepatitis C virus internal ribosome entry site)
04
Disease associations
Associated with Hepatitis C virus reproduction (by interacting with viral IRES)Mentioned in the context of Omsk Hemorrhagic Fever (database link only, no published mechanism)Occasionally found differentially expressed in cancer studies (e.g., gastric cancer), but not as a driver or central therapeutic targetNo established role in neurodegenerative, cardiovascular, inflammatory, or infectious disease outside generic ribosome involvement
05
Safety considerations
None specific to RPL18A.General safety concerns for ribosomal protein targeting would involve inhibition of protein synthesis and cytotoxicity, but RPL18A is not selectively targeted therapeutically
06
Interacting drugs
None directly. No drugs are reported to specifically target RPL18A
1 more in the full profile.
07
Biomarkers
None established for patient selection or efficacy monitoringChanges in ribosomal protein expression may occur in cancer or viral infection, but RPL18A is not a recognized clinical biomarker
Beyond the preview
Go deeper on 60S ribosomal protein L18a (RPL18A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 60S ribosomal protein L18a (RPL18A).